These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8438463)

  • 1. Human interleukin-2-IgM heavy-chain-fusion proteins are cytotoxic for cells expressing the IL2 receptor.
    Vie H; Gauthier T; Breathnach R; Bonneville M; Godard A; Dietrich J; Karam G; Gesnel MC; Peyrat MA; Jacques Y
    Transplant Proc; 1993 Feb; 25(1 Pt 1):741-2. PubMed ID: 8438463
    [No Abstract]   [Full Text] [Related]  

  • 2. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).
    Hank JA; Surfus JE; Gan J; Jaeger P; Gillies SD; Reisfeld RA; Sondel PM
    Clin Cancer Res; 1996 Dec; 2(12):1951-9. PubMed ID: 9816154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
    Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
    Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of a potentially immunosuppressive rat interleukin-2 immunoglobulin M fusion molecule.
    Parker KE; Cuturi MC; Soulillou JP
    Transplant Proc; 1993 Feb; 25(1 Pt 1):774-5. PubMed ID: 8438476
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
    Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
    Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formation of an active form of the interleukin-2/15 receptor beta-chain by insertion of the intracisternal A particle in a radiation-induced mouse thymic lymphoma and its role in tumorigenesis.
    Ukai H; Ishii-Oba H; Ukai-Tadenuma M; Ogiu T; Tsuji H
    Mol Carcinog; 2003 Jun; 37(2):110-9. PubMed ID: 12766910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
    Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
    Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both the alpha and beta chains of high-affinity interleukin 2 receptors are located in intracellular vesicles when their ligand is endocytosed.
    Ferrer M; Hémar A; Duprez V; Hellio R; Dautry-Varsat A
    Eur J Cell Biol; 1993 Apr; 60(2):276-82. PubMed ID: 8330625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemically engineered bispecific antibody directed at the p55 and p75 chains of the human interleukin 2 receptor: specific high-affinity cross-linking of p55/p75 complexes and high blocking effect on IL2-induced T cell proliferation.
    François C; Boeffard F; Jacques Y
    Transplant Proc; 1993 Feb; 25(1 Pt 1):815-6. PubMed ID: 8438495
    [No Abstract]   [Full Text] [Related]  

  • 10. Expression of fusion IL2-B7.1(IgV+C) and effects on T lymphocytes.
    Kong L; Li Y; Yang Y; Li K
    Biochem Cell Biol; 2007 Dec; 85(6):685-95. PubMed ID: 18059527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel design of targeted endocrine and cytokine therapy for breast cancer.
    Zhang G; Li W; Holle L; Chen N; Chen WY
    Clin Cancer Res; 2002 Apr; 8(4):1196-205. PubMed ID: 11948133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
    Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
    Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Third French Workshop on interleukin 2: joint report.
    Jacques Y; Soulillou JP
    Lymphokine Res; 1985; 4(2):159-67. PubMed ID: 3873589
    [No Abstract]   [Full Text] [Related]  

  • 14. Redirecting effector T cells through their IL-2 receptors.
    Lustgarten J; Marks J; Sherman LA
    J Immunol; 1999 Jan; 162(1):359-65. PubMed ID: 9886407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
    Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
    Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient generation of autologous peripheral blood-derived cytotoxic T lymphocytes against poorly immunogenic human tumors using recombinant CD80-adenovirus together with interleukin 12 and interleukin 2.
    Mogi S; Ebata T; Setoguchi Y; Fujime M; Heike Y; Kohsaka T; Yagita H; Okumura K; Azuma M
    Clin Cancer Res; 1998 Mar; 4(3):713-20. PubMed ID: 9533541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of T cell proliferation and cytotoxicity by lymphokines.
    Männel DN; Falk W; Dröge W
    Lymphokine Res; 1985; 4(2):133-8. PubMed ID: 3923276
    [No Abstract]   [Full Text] [Related]  

  • 18. Receptor-mediated endocytosis of IL-2 by PHA stimulated lymphocytes.
    Lee TP; Mookerjee BK
    Transplant Proc; 1989 Feb; 21(1 Pt 1):100-2. PubMed ID: 2784877
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting activated lymphocytes with an entirely human immunotoxin analogue: human pancreatic RNase1-human IL-2 fusion.
    Psarras K; Ueda M; Tanabe M; Kitajima M; Aiso S; Komatsu S; Seno M
    Cytokine; 2000 Jun; 12(6):786-90. PubMed ID: 10843765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
    Lee KD; Chen HW; Chen CC; Shih YC; Liu HK; Cheng ML
    Oncol Rep; 2006 May; 15(5):1211-6. PubMed ID: 16596189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.